Pompe Disease Therapeutic Market Global Industry Insights, Analysis, Trends and Forecast, 2017-2025
Increasing government initiatives is expected to augment growth of the pompe disease therapeutic market
Increasing government initiatives is expected to augment growth of the pompe disease therapeutic market
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Pompe</strong> <strong>Disease</strong> <strong>Therapeutic</strong> <strong>Market</strong>-<br />
GLOBAL INDUSTRY INSIGHTS, TRENDS, OUTLOOK,<br />
AND OPPORTUNITY ANALYSIS, <strong>2017</strong>-<strong>2025</strong><br />
© Coherent market <strong>Insights</strong>. All Rights Reserved
REPORT DESCRIPTION<br />
<strong>Pompe</strong> <strong>Disease</strong> <strong>Therapeutic</strong> <strong>Market</strong> – Overview<br />
Manufacturers are focusing on finding new solutions by exp<strong>and</strong>ing their pipeline to cater the dem<strong>and</strong> for<br />
pompe disease therapeutics market. For instance, in September, <strong>2017</strong>, Avrobio Inc. exp<strong>and</strong>ed their products<br />
pipeline with gene therapy to treat pompe disease by utilizing a proprietary lysosomal targeting sequence to<br />
deliver high levels of enzyme to lysosomes. Furthermore, in October <strong>2017</strong>, Amicus <strong>Therapeutic</strong>s received<br />
orphan drug designation to ATB200/AT2221 from the U.S. FDA for the treatment of <strong>Pompe</strong> disease. This<br />
novel treatment paradigm consists of ATB200, a unique recombinant human acid alpha-glucosidase (rhGAA)<br />
enzyme with optimized carbohydrate structures, particularly mannose-6 phosphate (M6P) to enhance uptake,<br />
co-administered with AT2221, a pharmacological chaperone.<br />
Increasing prevalence of pompe disease in many economies is expected to have a lucrative opportunities for<br />
pharmaceutical manufacturers to come with a tailored solution for diagnosis <strong>and</strong> treatment of disease.<br />
<strong>Pompe</strong> disease is an inherited Lysosomal Storage Disorder (LSD) caused by a deficiency of enzyme acid<br />
named alpha-glucosidase (GAA). This causes the glycogen to accumulate in different kinds of tissues,<br />
primarily into smooth muscles, skeletal muscles <strong>and</strong> cardiac muscle. It leads to muscle weakness, respiratory<br />
problems, <strong>and</strong> may also affects the liver <strong>and</strong> heart.<br />
© Coherent market <strong>Insights</strong>. All Rights Reserved
REPORT DESCRIPTION<br />
<strong>Pompe</strong> <strong>Disease</strong> <strong>Therapeutic</strong> <strong>Market</strong> Taxonomy:<br />
By Therapy Type:<br />
●<br />
●<br />
●<br />
Gene Therapy<br />
Enzyme Replacement Therapy (ERT)<br />
Chaperone-Advanced Replacement Therapy (CHART)<br />
By Administrational Route:<br />
●<br />
●<br />
Oral<br />
Parenteral<br />
Request for a sample copy @ https://www.coherentmarketinsights.com/insight/request-sample/1316<br />
© Coherent market <strong>Insights</strong>. All Rights Reserved
REPORT DESCRIPTION<br />
<strong>Pompe</strong> <strong>Disease</strong> <strong>Therapeutic</strong> <strong>Market</strong>: Key Players<br />
●<br />
●<br />
●<br />
●<br />
●<br />
●<br />
●<br />
Amicus <strong>Therapeutic</strong>s, Inc.<br />
Valerion <strong>Therapeutic</strong>s.<br />
LLC.<br />
Sanofi S.A.<br />
Oxyrane.<br />
Sangamo <strong>Therapeutic</strong>s, Inc.<br />
The high cost associated with the treatment <strong>and</strong> long duration of the treatment are the factors restraining growth of<br />
the pompe disease therapeutic market. For instance, according to a research paper published by Harvard School, in<br />
2016, Lumizyme accounted for US$ 100,000 per year for children <strong>and</strong> US$ 300,000 per year for adult treatments.<br />
Complete Report Details @<br />
https://www.coherentmarketinsights.com/ongoing-insight/pompe-disease-therapeutic-market-1316<br />
© Coherent market <strong>Insights</strong>. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS<br />
ABOUT US<br />
Coherent <strong>Market</strong> <strong>Insights</strong> is a global market intelligence <strong>and</strong> consulting organization<br />
focused on assisting its plethora of clients achieve transformational growth by helping<br />
them make critical business decisions. We are headquartered in India, with an office at<br />
the global financial capital in the U.S. Our client base includes players from across all<br />
business verticals in over 150 countries worldwide. We are uniquely positioned to help<br />
businesses around the globe deliver practical <strong>and</strong> lasting results through various<br />
recommendations about operational improvements, technologies, emerging market<br />
trends <strong>and</strong> new working methods. We offer both customized <strong>and</strong> syndicated market<br />
research reports that help our clients create visionary growth plans to provide traction to<br />
their business. We meticulously study emerging trends across various industries at both<br />
the global <strong>and</strong> regional levels to identify new opportunities for our clientele.<br />
SERVICES<br />
INDUSTRY ANALYSIS<br />
MARKET INTELLIGENCE<br />
SERVICES<br />
CUSTOMIZED<br />
RESEARCH<br />
CONSULT STUDIES<br />
SYNDICATED RESEARCH<br />
COUNTRY SPECIFIC<br />
STUDIES<br />
© Coherent market <strong>Insights</strong>. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS<br />
SECTOR COVERAGE<br />
Healthcare<br />
CLINICAL DIAGNOSTIC<br />
HEALTHCARE IT<br />
MEDICAL DEVICES<br />
MEDICAL IMAGING<br />
Chemicals & Materials<br />
PHARMACEUTICAL<br />
Bulk Chemicals Advanced Materials Speciality <strong>and</strong> Fine Chemicals<br />
Green Chemicals<br />
Food Ingredients<br />
Cosmetic Ingredients<br />
Polymers & Resins<br />
© Coherent market <strong>Insights</strong>. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS<br />
KEY STATS<br />
100+<br />
<strong>Insights</strong> Published Per Year<br />
150+<br />
Consulting Projects Till Date<br />
125+<br />
Clients Worldwide Per Year<br />
RESEARCH SOLUTIONS<br />
CONSULT<br />
PROJECTS<br />
SURVEY<br />
RESEARC<br />
H<br />
FEASIBILITY<br />
STUDIES<br />
EXCEL<br />
FORECAST<br />
DATABASE<br />
GLOBAL<br />
REPORTS<br />
COUNTRY<br />
ANALYSIS<br />
CUSTOMIZED<br />
SOLUTIONS<br />
COMPETITIVE<br />
ASSESSMENT<br />
110+<br />
Analysts <strong>and</strong> Contract Consultants<br />
TECHNOLOGY<br />
SNIPPETS<br />
Coherent <strong>Market</strong> <strong>Insights</strong> excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, <strong>and</strong><br />
food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across<br />
various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our<br />
clients achieve better outcomes with uniquely designed <strong>and</strong> highly customized solutions. Our coverage includes insights that help our clients ensure sustained<br />
growth in developed markets <strong>and</strong> also key inputs to help them tap into emerging markets <strong>and</strong> exploit the plethora of opportunities posed therein.<br />
© Coherent market <strong>Insights</strong>. All Rights Reserved
To k no w mor e abo ut us, v isit o ur web site:<br />
www.coh er en tmark etinsig hts.com<br />
For sales q ueries o r new top ics email u s o n :<br />
sales@coh er en tmark etinsig hts.co m<br />
Fo r o th er q uer ies co n tact:<br />
Mr. Sh ah<br />
( Man ag er - Business Dev elo pment)<br />
Co herent Mark et Insig hts<br />
sales@coh er en tmark etinsig hts.co m<br />
+1 -2 06 -7 0 1- 67 02<br />
THANK YOU<br />
© Coherent market <strong>Insights</strong>. All Rights Reserved
Change language